Background: Interleukin (IL)‐31 is an important mediator in canine atopic dermatitis (cAD) and also may be dysregulated in other allergic diseases.Hypothesis/Objectives: To demonstrate the efficacy and safety of lokivetmab (canine anti‐IL‐31 monoclonal antibody) for treatment of pruritus associated with allergic dermatitis in dogs.Animals: Dogs that were at least moderately pruritic with a presumptive diagnosis of allergic dermatitis were enrolled in Portugal, Hungary, France and Germany by 12 primary care practitioners and two veterinary dermatology referral specialists.Methods and materials: Dogs were randomised to receive either placebo (saline) or lokivetmab (1.0–3.3 mg/kg) by subcutaneous injection on Day (D)0. Owners evaluated pruritus using a validated Visual Analog Scale (pVAS) daily until D7 and then weekly until D28. The severity of dermatitis was assessed by the investigators using a modified VAS on D0, D7, D14 and D28.Results: Beginning at D1, owner‐assessed pVAS least square means were significantly reduced in the treatment group versus the placebo group (57.7% versus 21.8% reduction on D28). For all time points, investigator‐assessed VAS means were significantly reduced in the lokivetmab group versus the placebo group (57.1% versus 20.5% reduction on D28). Overall, the occurrence of adverse health events during the evaluation period was comparable between the two groups.Conclusions and clinical importance: Lokivetmab is a safe and efficacious treatment for dogs with allergic dermatitis.
Rapid and high efficacy against ticks after attachment has the potential to aid in the prevention of tick-borne pathogen transmission. The objective of the study was to assess the speed-of-kill of Simparica Trio® against Ixodes ricinus. On Study Day 0, sixteen Beagle dogs were treated with placebo or Simparica Trio at the minimum approved dose (1.24 mg/kg sarolaner, 0.024 mg/kg moxidectin, 5 mg/kg pyrantel). Each dog was infested with 50 unfed viable adult I. ricinus. Efficacy was assessed by in situ tick counts at 12 hours and by counts with removal of the ticks at 24 hours after treatment (Study Day 1) or re-infestation (Study Days 7, 14, 21, 28 and 35 after treatment). Efficacy was evaluated based on reduction of mean live tick counts in the treated versus the placebo group. Against a pre-existing infestation, treatment provided significant reduction in live tick counts (96.2%) within 24 hours after treatment. For subsequent re-infestations, live tick counts were also significantly reduced with efficacy >90% at 24 hours, for at least 36 days. At 12 hours, the number of tick counts was significantly lower in the treated group compared to the placebo group for two weeks, without achieving 90% reduction. A single treatment with Simparica Trio at the minimum approved dose (1.24 mg/kg sarolaner, 0.024 mg/kg moxidectin, 5 mg/kg pyrantel) is efficacious against I. ricinus within 24 hours after treatment and subsequent re-infestations for 36 days.